Gilead and Novo Nordisk expand collaboration in NASH therapeutics
Over the current book year the total revenue from the company in Foster City will be 24.79 billion USD (consensus estimates). This is slightly more than 2020's revenue of 24.69 billion USD.
Historical revenues and results Gilead Sciences plus estimates 2020
The analysts expect for 2021 a net profit of 9.02 billion USD. The majority of the analysts expects for this year a profit per share of 7.17 USD. Based on this the price/earnings-ratio is 8.92.
Huge dividend Gilead Sciences
Per share the analysts expect a dividend of 2.74 USD per share. Thus the dividend yield equals 4.28 percent. The average dividend yield of the biotech companies is a moderate 0.37 percent.Most recent target prices around 73 USD
The most recent recommendations for the biotech company are from Morgan Stanley , RBC Capital Markets and Credit Suisse .Based on the current number of outstanding shares Gilead Sciences 's market capitalization 81.01 billion USD. The Gilead Sciences stock was the past 12 months quite unstable. Since last March the stock is 10 percent lower. This year the stock price moved between 57 and 86 dollar.
Price data Gilead Sciences 2007-2021
Click here for dividend Gilead Sciences. On Thursday the stock closed at 63.99 USD.
Analist.nl Nieuwsdienst: +31 084-0032-842
nieuws@analist.nl
Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. Analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.
| About us | Network | Partners |
| Fpgroup.nlinfo@analist.nlRSS feedContactIntellectual Property Photos |
Analist.nlLinksISIN
|
MorningstarPrudena.comAAII.comNASDAQvwd GroupEuronextBATS Chi-x
|
